Search results
Showing 241 to 255 of 529 results for drug monitoring
Heart valve disease presenting in adults: investigation and management (NG208)
This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).
NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux
Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease (HTG749)
Evidence-based recommendations on laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease. This involves placing an implant on the outside of the upper part of the stomach wall using keyhole surgery.
View recommendations for HTG749Show all sections
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)
Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.
Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)
This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD–OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
In a virtual ward setting, you make assessments at home to support clinical decision-making. Our guidance can help you give advice by highlighting areas to consider and standards of care.